XLRN Acceleron Pharma Inc

By Colin Kellaher

Bristol-Myers Squibb Co. (BMY) and Acceleron Pharma Inc. (XLRN) Friday said the U.S. Food and Drug Administration has reversed course on a planned advisory committee review of the use of the anemia drug Reblozyl in patients with myelodysplastic syndromes.

The companies said the change follows a late-cycle review meeting on Wednesday, adding that the target action date for the supplemental biologics license application remains April 4, 2020.

Bristol-Myers and Acceleron on Tuesday had said that the FDA's advisory panel on oncologic drugs would review the sBLA at its meeting on Dec. 18.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 06, 2019 12:30 ET (17:30 GMT)

Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024